[144] Boston Scientific Corp. SEC Filing

Rhea-AI Filing Summary

Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.

The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.

Positive

• Complete transaction details provided: acquisition date, nature (stock option exercise), broker, approximate sale date, and aggregate value are all disclosed
• Prior sales disclosed: three prior dispositions in the past three months are listed, supporting transparency

Negative

• Significant insider selling: 156,372 shares sold in the past three months totaling $16,985,599.64 in gross proceeds
• Large proposed sale: 50,000 shares (~$5.27 million) to be sold on 09/02/2025, which may be material depending on holder context

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 disclosure showing an insider sale and recent related transactions; appears administratively compliant.

The Form 144 documents a proposed sale under Rule 144 of 50,000 common shares acquired by stock option exercise on the same day, with the broker and planned exchange specified. The filing lists three prior sales by the same individual in the past three months totaling 156,372 shares and about $16.99 million gross proceeds. From a compliance perspective, the form provides the core required elements: acquisition date, nature of acquisition, broker name and address, number of shares, aggregate value, and approximate sale date. No additional material company information, change in control, or financial results are provided in this notice.

Equity Transactions Specialist

TL;DR: Material size of insider sales this quarter is notable but the filing itself is a standard disclosure of planned and recent dispositions.

The disclosure indicates concentrated insider selling activity across three months with sizeable proceeds. The single proposed sale equals roughly $5.27 million and follows prior monthly dispositions, which may be relevant for liquidity or personal financial planning of the seller. The form does not state the seller's corporate role or any trading plan date, and it confirms payment for the newly acquired shares was in cash. No forward-looking statements or issuer operational details are included, limiting interpretive scope to transaction mechanics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	5271415.00	1481751634	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	ISSUER			50000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOSEPH M FITZGERALD 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234	Common	08/01/2025	50000	5231665.00
JOSEPH M FITZGERALD 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234	Common	07/01/2025	50000	5348310.00
JOSEPH M FITZGERALD 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234	Common	06/04/2025	56372	5799624.64

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Boston Scientific (BSX) report?

The Form 144 reports a proposed sale of 50,000 common shares via Morgan Stanley Smith Barney on the NYSE with aggregate market value $5,271,415.00 and an approximate sale date of 09/02/2025.

How were the 50,000 shares acquired according to the filing?

The filing states the 50,000 shares were acquired on 09/02/2025 through a stock option exercise and paid for in cash.

Has the seller made other sales recently?

Yes. JOSEPH M FITZGERALD sold 50,000 shares on 08/01/2025 (gross proceeds $5,231,665.00), 50,000 on 07/01/2025 (gross proceeds $5,348,310.00), and 56,372 on 06/04/2025 (gross proceeds $5,799,624.64), totaling 156,372 shares.

Which broker and exchange are named for the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, and the exchange is the NYSE.

Does the filing disclose any material undisclosed company information?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed; the filing itself contains no issuer operational or financial details.